We present 60 patients with refractory (n ¼ 8) or relapsed (n ¼ 52) adult ALL who received allogeneic hematopoietic SCT (HSCT) with (n ¼ 41) or without (n ¼ 19) prior reinduction chemotherapy. In our center, omission of reinduction is recommended if a suitable donor is promptly available, tumor burden is moderate and disease features suggest a highly aggressive course. Overall survival (OS) of the whole cohort at 1, 2 and 5 years was 42, 33 and 28%, respectively. Leukemia-free survival at 1, 2 and 5 years was 37, 33 and 24%. Deaths were due to relapse (n ¼ 25), acute or chronic GVHD (n ¼ 7), infections (n ¼ 8) or toxicity (n ¼ 4). Interestingly, patients who did not receive reinduction before HSCT had better outcomes than patients who received reinduction with OS at 1, 2 and 5 years being 58 vs 34%, 47 vs 25% and 47 vs 18%, respectively (P ¼ 0.039). Importantly, even achievement of a second CR after reinduction was not associated with improved survival compared to patients directly proceeding to HSCT. We conclude that patients who undergo HSCT for refractory or relapsed ALL can achieve longterm survival. In selected patients, reinduction chemotherapy can be omitted if immediate HSCT is feasible.
Introduction
In the last four decades the results of induction and consolidation chemotherapy for ALL have improved steadily and remission rates have reached 80-90% in adults and children. 1, 2 However, in adult ALL, relapse is still common and long-term survival is less than 40%. [3] [4] [5] [6] [7] Salvage chemotherapy can induce CR in relapsed ALL but remission duration is short with a median disease-free survival of only 2-8 months and long-term overall survival (OS) rates of less than 10%. [8] [9] [10] [11] Therefore, after conventional salvage therapy and achievement of second CR (CR2) most centers proceed to allogeneic hematopoietic SCT (HSCT) to increase treatment intensity and to exploit a GVL effect. Although this approach leads to cure rates of up to 25%, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] it is not clear if salvage chemotherapy before HSCT is required for all patients or if some patient subgroups might benefit from immediate HSCT without prior reinduction attempts. This latter strategy has been suggested by studies in AML, where patients who did not receive reinduction had a better outcome than patients who did receive reinduction, even if CR2 could be achieved. [18] [19] [20] To date, no prospective study has evaluated benefits and risks of reinduction chemotherapy before HSCT in relapsed or refractory ALL and only scanty retrospective data exist. In our center, we generally prefer the use of reinduction chemotherapy before HSCT in all patients with advanced ALL. However, omission of reinduction is recommended to patients if a suitable donor is promptly available, tumor burden is moderate and disease features such as high-risk cytogenetics and early relapse suggest a highly aggressive course. Here, we present a retrospective analysis of 60 patients with advanced ALL (primary refractory disease: n ¼ 8, first relapse: n ¼ 52) who were treated according to this allocation scheme between 1995 and 2006, with 41 patients receiving reinduction before HSCT and 19 patients not receiving reinduction.
Patients and methods

Patients
Data from 60 adult patients with advanced ALL (primary refractory disease: n ¼ 8, first relapse: n ¼ 52) who received an allogeneic HSCT at our center were retrospectively analyzed (Table 1) . Median age was 29.1 years (range: 17.0-54.1). All patients had received initial treatment according to the German Multicenter Study Group for Adult ALL protocols (GMALL). 21, 22 Risk group at time of diagnosis according to GMALL criteria was standard risk in 27 patients, high risk in 19 patients and very high risk (Ph þ ) in 14 patients. The BM was the sole site of relapse in most patients (n ¼ 45); however, some patients had additional infiltrates in the meninges (n ¼ 4), the skin (n ¼ 2), the mediastinum (n ¼ 2), the kidney (n ¼ 1), the pleural cavity (n ¼ 1) and the testes (n ¼ 1). Sites of extramedullary disease manifestation without BM infiltration were the meninges (n ¼ 1), the testes (n ¼ 1), the mediastinum (n ¼ 1) and the pelvis (n ¼ 1).
Forty-one patients received reinduction chemotherapy before HSCT (group I), whereas 19 patients were transplanted with active disease without reinduction (group II). Omission of reinduction was considered in patients with a promptly available suitable donor and only moderate blast counts (o50%) presenting with high risk features, such as short duration of first CR (o18 months) 12 or high risk cytogenetics (Ph þ , complex aberrant karyotype, t [4;1] ). The administration of reinduction chemotherapy before HSCT was preferred in all other patients.
The choice of a specific reinduction regimen for patients in group I depended on the study period, prior therapies and the decision of the referring physician. The regimen primarily used included repeat courses of the primary induction regimen, 21 specific GMALL reinduction protocols 12, 21 or FLAG/IDA. 23 In cases of reinduction failure (19 of 41 patients in group I), patients advanced directly to HSCT without further reinduction attempts.
HSCT
All transplants were performed between July 1995 and April 2006 at the Department of Hematology and Oncology, Charite´-University Medicine Berlin, Campus Mitte and Campus Virchow-Klinikum, Berlin, Germany.
As the preparative regimen for HSCT, 56 patients received standard high-dose conditioning based on 6 Â 2 Gy TBI plus either 2 Â 60 mg/kg CY (n ¼ 42) or 60 mg/kg etoposide (n ¼ 3) or a combination of 2 Â 50 mg/kg CY and 50 mg/kg etoposide (n ¼ 11). One patient received 4 Â 4 mg/kg BU and 2 Â 60 mg CY. Owing to older age (455 years) and/or comorbidities, three patients received reduced-intensity conditioning with 6 Â 30 mg/m 2 fludarabine, 2 Â 4 mg/kg BU and 4 Â 10 mg/kg rabbit antithymocyte globulin (Fresenius, Germany) ( Table 2) . 24 Transplants were from related (n ¼ 24) or unrelated (n ¼ 36) donors and were HLA-matched (6/6 or 10/10 antigens) (n ¼ 55) or -mismatched (n ¼ 5) according to serologic typing (before 1997) or high-resolution genotyping (from 1997). Either BM (n ¼ 19) or PBSCs (n ¼ 41) were used as the stem cell source. After HSCT, G-CSF was given to patients receiving reduced-intensity conditioning or patients with unrelated donors, at a dose of 5 mg/kg/day from day þ 5 until leukocyte counts reached 1/nl ( Table 2 ).
GVHD and donor leukocyte infusions
Graft-versus-host disease prophylaxis consisted of CsA and short-course MTX for patients receiving high-dose conditioning and HSCT from related donors and CsA/MTX/ prednisone for high-dose conditioning and unrelated donors. CsA and mycophenolate mofetil were given to patients who received reduced-intensity conditioning.
Acute GVHD and chronic GVHD (cGVHD) were graded according to the standard criteria. 25, 26 cGVHD was only assessed if patients survived more than 100 days after transplantation.
All patients transplanted after 1997 were scheduled to receive prophylactic donor lymphocyte infusions (DLIs) under the following conditions: availability of DLI, patient consent, absence of infection and leukemic relapse and Allogeneic SCT in advanced ALL TH Terwey et al absence of acute or chronic GVHD after cessation of immunosuppression. 27 DLIs were given in escalating doses every 4 weeks, not earlier than day 60 after HSCT (median cumulative dose: 5.5 Â 10 7 CD3 þ cells per kg). In total, 18 patients received prophylactic DLIs.
Statistics
Data were analyzed as of 15 August 2007. Statistical analysis was performed using SPSS 14.0 (SPSS, Chicago, USA) and GraphPad 4.0 (GraphPad Software Inc., San Diego, USA). The level of significance was 0.05 (two-sided).
Patient and treatment characteristics were compared with the nonparametric Mann-Whitney U-test for continuous data and Fisher's exact test and w 2 test for categorical data. Results are given with median and range.
Overall survival was measured from the date of transplantation to the date of death from any cause. Leukemia-free survival was defined as survival from the date of transplantation, while in continuous CR. For surviving patients data were censored at the date of last follow-up. Survival data were analyzed according to Kaplan-Meier and tested univariately using the log-rank test. Multivariate analysis was performed using the Cox proportional hazard regression model. Prognostic variables examined were sex, age, diagnosis, donor type and stem cell source. First, for each potential confounder a model with two variables, the confounder and reinduction chemotherapy, was calculated. Then, forward and backward variable selection (inclusion P ¼ 0.05, exclusion P ¼ 0.10) was applied.
The prognostic value of cGVHD and application of DLI was evaluated using the landmark method, which eliminates the bias that length of survival influences the chance of developing cGVHD or receiving DLIs. 28 
Results
Sixty adult patients with ALL at first relapse (n ¼ 52, 87%) or primary refractory ALL (n ¼ 8, 13%) were included in this retrospective analysis. Forty-one of 60 patients (68%) received reinduction therapy before HSCT (group I), whereas 19 of 60 patients (32%) were transplanted without any reinduction attempt (group II). In group I, CR2 could be achieved and maintained until HSCT in 22 of 41 patients (54%), whereas 19 of 41 patients (46%) were either refractory to salvage chemotherapy (17 of 19) or had an immediate relapse thereafter (2 of 19). Groups I and II were similar for the distribution of sex, age, ALL lineage and disease status (Table 1) . However, reflecting our selection criteria, in group II median time-to-first-relapse was significantly shorter than in group I (4.7 vs 12.6 months, P ¼ 0.023), fewer blasts were present in the BM at the time of treatment allocation (25 vs 60%, P ¼ 0.038) and significantly more patients belonged to the high-risk category (53 vs 22%, P ¼ 0.0017). Also, time-fromrelapse-to-HSCT was significantly shorter in group II (0.5 vs 3.1 months, Po0.0001). However, owing to reinduction chemotherapy, blast counts at time of transplantation were significantly higher in group II than in group I (25 vs 0%, P ¼ 0.012) ( Table 1) . Importantly, all transplant character- istics (conditioning regimen, donor type, stem cell source, administration of prophylactic DLIs) were similar in both groups (Table 2) . Currently, after a median follow-up of the survivors of 64.7 months (range: 16.5-140.5) and after a median followup of all patients of 9.3 months (0.7-140.5), 16 of 60 patients (27%) remain alive (Table 3) . Projected OS of the whole cohort at 1, 2 and 5 years was 42, 33 and 28%, respectively, with a median OS of 9.3 months (0.7-140.5). Leukemia-free survival at 1, 2 and 5 years was 37, 33 and 24%, respectively (Figure 1 ). Deaths were due to relapse (n ¼ 25, 42%), acute or cGVHD (n ¼ 7, 12%), infections (n ¼ 8, 13%) or toxicity (n ¼ 4, 7%) ( Table 3 ).
In the subgroup comparison of patients who either did or did not receive reinduction chemotherapy before HSCT (groups I and II), it was found that patients in group II had better outcomes than patients in group I with OS at 1, 2 and 5 years being 58 vs 34%, 47 vs 25% and 47 vs 18%, respectively (P ¼ 0.039, hazard ratio ¼ 0.49 (95% confidence interval: 0.28-0.97)) ( Figure 2 ). Median OS was 14.2 months (1.1-108.9) in group II compared to 8.4 months (0.7-140.5) in group I (P ¼ 0.039, ratio of median OS ¼ 1.69 (95% confidence interval: 1.20-2.19)). Similar trends were observed when OS was measured from the date of relapse rather than from the date of transplantation (data not shown). In multivariate analysis with sex, age, diagnosis, donor type and stem cell source as potential confounders, application of reinduction chemotherapy remained an independent negative prognostic factor (data not shown).
The improvement in OS in group II was associated with a reduced incidence of non-leukemic deaths (26 vs 34%) and reduced relapse mortality (26 vs 49%). However, these differences did not reach statistical significance (Table 3) . Importantly, a nonsignificant trend towards improved outcome and less relapse mortality was still maintained if group II was compared to patients with successful reinduction chemotherapy who were transplanted in CR2 (P ¼ 0.1342) (Figure 3) . Patients who failed reinduction and who were transplanted with active disease had an inferior outcome with a 5-year OS of only 8% (P ¼ 0.034) (Figure 3 ).
In the whole cohort, acute GVHD grades I and II occurred in 25 of 60 patients (42%) and acute GVHD grades III and IV developed in 15 of 60 patients (25%) with no significant differences among the subgroups (Table 3) . Extensive cGVHD was observed in 25 of 49 analyzable Table 3 Outcome after HSCT Table 3 ). In univariate Kaplan-Meier survival analysis of the whole cohort using log-rank statistics, it was found that patients who developed cGVHD had significantly better outcomes than patients without cGVHD (5-year OS 45 vs 24%, P ¼ 0.0046). However, statistical significance was lost when the outcome was compared using the more appropriate landmark method. Similar effects were noted for the application of prophylactic DLIs (Table 4) . In further univariate Kaplan-Meyer analysis of a variety of patient and treatment characteristics, age below 30 years was the only positive predictors of survival in one subgroup (Table 4) .
Discussion
Long-term survival of patients with refractory or relapsed adult ALL treated with chemotherapy alone is generally poor. [8] [9] [10] [11] In a large retrospective analysis of 314 adult patients with advanced ALL, projected OS at 5 years was only 3% and median OS was only 5 months. 9 Therefore, if a compatible donor can be found and no contraindications exist, it is current practice to proceed to allogeneic HSCT once complete remission is achieved by salvage therapy. 13, 14 Although most studies indicate that achievement of remission before HSCT is optimal for long-term disease control, 15, 16 with even low levels of minimal residual disease impairing outcome, 29, 30 there are compelling arguments for immediate HSCT without prior reinduction attempts. First, depending on the patient population and the applied regimen, up to 50% of patients can be refractory to reinduction or will have an early relapse thereafter. [8] [9] [10] 13, 14 Second, reinduction regimens can cause considerable treatment-related mortality reaching up to 20%. 9 Third, reinduction can cause extensive organ toxicity sometimes delaying or even prohibiting the application of subsequent HSCT or increasing the complication rates. 13 And finally, reinduction regimens can cause the emergence of chemotherapy-resistant leukemia clones reducing the potential effects of a subsequent HSCT. 31, 32 Overall, some studies reported that less than 50% of patients admitted for salvage treatment actually underwent the intended HSCT, even if the treatment protocol was especially designed with this aim. 12, 13, 33, 34 Considering these arguments, we usually recommend immediate HSCT to patients with a promptly available suitable donor, moderate tumor burden and disease features suggesting a highly aggressive course. As shown here, this strategy proved successful as patients who did not receive reinduction had a substantially better outcome than patients who received reinduction, with a 5-year OS of 47% compared to 18% and a median OS of 14.2 months compared to 8.4 months. Patients who achieved CR2 after reinduction had a 5-year OS of 25%, whereas patients who failed reinduction and who were therefore transplanted with active disease had a 5-year OS of 8%, both results being in the range of previously published data. 10 OS of the whole cohort irrespective of previous reinduction therapy was 27%, which is comparable to other studies 11, 15, 16, 35 and which underscores the therapeutic potential of HSCT in this high-risk patient population.
The reasons for the discrepancy between our findings of improved OS in the no reinduction group and the previous studies, which generally concluded that HSCT in CR2 is superior to HSCT in active disease 15, 16 are not totally clear. However, other groups have already shown that long-term survival rates of more than 20% can be achieved when HSCT is performed in active disease. 10, 36, 37 We argue that our patients had an additional survival benefit because toxicity through application of reinduction chemotherapy was avoided and most patients were still in early relapse at time of HSCT (median blasts at HSCT 25%). Immediate HSCT (median time-from-relapse-to-HSCT 0.5 months) could be performed as patients mainly belonged to the high-risk category where a donor search had already been performed at diagnosis. Better survival with shorter times from diagnosis to transplantation has been previously described. 15 Furthermore, the high OS rate of patients transplanted with active disease and no reinduction attempt may be due to the high incidence of extensive cGHVD in this subgroup (75 vs 39% in the reinduction group), which possibly correlates with a more potent GVL effect. 38, 39 Whether this increased incidence of cGHVD has a biological explanation or whether it is due to statistical effects is difficult to say as we have not found a difference in conditioning regimen, donor type, stem cell source or use of prophylactic DLIs between the two groups. Kaplan-Meyer survival analysis suggested that the development of cGVHD leads to significantly better OS. However, to face cGVHD, patients have to survive until this time point and patients who die rapidly will be incorrectly excluded from the analysis. The landmark method 28 can correct for this bias and when applied no significant differences in OS were seen.
Donor lymphocyte infusion has only limited activity in ALL once overt hematological relapse has occurred. 40 However, when given in a prophylactic setting, DLI can convert mixed to complete donor chimerism suggesting the existence of a considerable GVL effect. 27, 41 We therefore began to use prophylactic DLIs in high-risk ALL patients in 1997 and have included patients in a prospective pilot study since 1998. 42 However, due to small patient numbers in the present trial, we are not able to draw definite conclusions about the role of DLI in patients with advanced ALL. Whether the high chimerism conversion Table 4 Influence of patient and treatment characteristics on outcome rate observed after DLI 42 leads to a lower relapse risk with better OS or whether these effects are counterbalanced by the high incidence of GVHD has to be determined in larger prospective randomized trials.
Besides an evaluation of the efficacy of reinduction chemotherapy, we also determined risk factors, which had an impact on the outcome of HSCT for advanced ALL. In our analysis, only age below 30 years had prognostic significance in one subgroup. Risk factors such as duration of first CR and percentage of blasts at time of transplantation, which were previously shown to be relevant for HSCT 43 were not important in our patients, even when multiple cutoffs were analyzed.
Important limitations of our analysis are the small patient number and the retrospective single-institution design. Therefore, our results are susceptible to sources of bias, which have to be discussed from a statistical point of view.
(1) Selection of study population: This was not a randomized study. However, retrospective comparisons showed that important pretreatment characteristics, such as sex, age, ALL lineage and disease status, were evenly distributed between the groups. The observed differences in risk group at diagnosis, time-to-relapse and blasts-at-HSCT were due to group definitions and clearly gave an advantage to the reinduction cohort. This strongly argues against an important influence of patient selection on our results. However, relevant differences between both groups may not have become significant due to the small statistical power of the comparisons. Moreover, as in any retrospective nonrandomized study, differences among the groups might have existed, which were not readily apparent and were therefore not analyzed. (2) Reinduction therapy: In most cases, reinduction chemotherapy was done in the referring centers and not in the transplant center. We did not collect nor did we compare data on the specific reinduction regimens used. The general feasibility of our approach cannot be directly inferred from this study as we do not have access to data from patients who died before they could be hospitalized in our center for transplantation. In particular, we cannot say whether those patients received reinduction therapy or not. Thus, we cannot say whether there is a bias and which treatment group would benefit from this possible bias.
In summary, patients who undergo allogeneic HSCT for relapsed ALL can achieve substantial long-term survival, which is projected at about 27% at 5 years. Importantly, in selected cases with a low tumor burden and an immediately available donor, HSCT can be performed without prior reinduction chemotherapy, as 5-year OS in these patients was 47%. However, the application of salvage therapy before HSCT remains the standard of care in all other patients and is always required to temporarily suppress disease progression, if time is needed for a donor search or if transplant capacity is limited. Patients who fail reinduction chemotherapy have a poor prognosis with 5-year OS of 8%, suggesting that HSCT in these cases is not beneficial. To further clarify the role of reinduction chemotherapy in advanced ALL, a prospective, randomized clinical study with carefully chosen risk stratification seems to be scientifically necessary and ethically justified. Considering the rarity of the disease, a multicenter approach will be required.
